Presented at EASD 61th Annual Meeting, Vienna, September 2025
K. Su Khin 1 , T. Crabtree 2 , A. Liarakos 1 , W. Ahmad 3 , A. Maliekal 3 , V. Oguntolu 4 , A. Gough 5 , S. Krishnasamy 6 , H. Reid 7 , K. Adamson 7 , G.R. Mudiyanselage 5 , E. Wilmot 8 , I. Idris 9 , R.E.J. Ryder 10
Presented at EASD 61th Annual Meeting, Vienna, September 2025
Alexandros L. Liarakos1,2, Thomas S.J. Crabtree1, Tomás P. Griffin3,4, Sufyan Hussain5,6,7, Jackie Elliott8,9, Mark L Evans10,11, Robert E.J. Ryder14, Pratik Choudhary3,4, Emma G. Wilmot1,2
Developed by Getting It Right First Time (GIRFT), this guide is to support the health and wellbeing of people with diabetes as they await surgery.
The Getting It Right First Time (GIRFT) Diabetes Emergency Surgery Pathway, was developed as part of the Improving the Perioperative Pathways of People with Diabetes (IP3D) program. It is a set of resources and guidelines to improve care for surgical patients with diabetes, particularly in emergency settings.
Watch the video guides below, tailored for:
The conference has been instigated and organised by ABCD.
The European Association for the Study of Diabetes (EASD) Early Career Academy invites early career researchers and clinicians to contribute to an upcoming webinar series presenting highlights from the EASD 2025 Annual Meeting.
Levemir® insulin, in both its Penfill® and Flexpen® presentations, is to be discontinued, with an anticipated supply end date of December 2026. A Medicine Supply Notification (MSN/2025/036U) has been issued regarding the discontinuation.
In response to this, the Association of British Clinical Diabetologists and the Primary Care Diabetes & Obesity Society have published joint guidance from a multidisciplinary team of healthcare professionals, which aims to support clinicians in appropriately selecting and safely prescribing alternative insulin therapy.
Levemir® insulin, in both its Penfill® and Flexpen® presentations, is to be discontinued, with an anticipated supply end date of December 2026. A Medicine Supply Notification (MSN/2025/036U) has been issued regarding the discontinuation.
In response to this, the Association of British Clinical Diabetologists and the Primary Care Diabetes & Obesity Society have published joint guidance from a multidisciplinary team of healthcare professionals, which aims to support clinicians in appropriately selecting and safely prescribing alternative insulin therapy.
